The price of Rinvoq (upadacitinib) varies depending on factors such as dosage, quantity, and insurance coverage. The average retail price for a 30-day supply of Rinvoq 45 mg extended-release tablets is approximately $6,500 to $7,000 [1].
How much does Rinvoq cost without insurance?
Without insurance, the cost of Rinvoq can be significantly higher. A single prescription for a 30-day supply can range from $6,500 to over $7,000 [1]. Patient assistance programs and manufacturer coupons may be available to help reduce out-of-pocket expenses for eligible individuals.
What insurance plans cover Rinvoq?
Rinvoq is covered by many commercial insurance plans, Medicare, and Medicaid. However, coverage details and patient co-pays can differ significantly between plans. It is advisable to check with your specific insurance provider or a pharmacist to confirm coverage for Rinvoq and to understand your estimated out-of-pocket costs.
Are there Rinvoq discount programs or coupons?
AbbVie, the manufacturer of Rinvoq, offers the Rinvoq Savings Card program. This program can help eligible patients with commercial insurance reduce their co-pay to as little as $5 per month. Eligibility requirements and program terms apply, and information can be found on the Rinvoq website [1].
What is the price difference between Rinvoq and other similar drugs?
The pricing of JAK inhibitors, including Rinvoq, is generally in a similar range. For example, Xeljanz (tofacitinib) and Cibinqo (abrocitinib) are other JAK inhibitors used for similar conditions, and their pricing is comparable to Rinvoq. The specific cost can fluctuate based on the drug, dosage, and formulation.
When does the Rinvoq patent expire?
The patent landscape for drugs is complex and involves multiple patents covering different aspects of the drug, such as its composition of matter, manufacturing process, and methods of use. DrugPatentWatch.com tracks these patents, and specific expiry dates can be researched for detailed information [2]. Generally, compound patents for newer drugs like Rinvoq are often in effect for many years after approval.
What are the approved uses for Rinvoq?
Rinvoq is approved for the treatment of several autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn's disease [1].
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com